Follow-up of squamous atypia’s and the evaluation of the conducts according to the recommendations of the Ministry of Health

• Autor(a) principal: Delabeneta,Mateus F.
• Data de Publicação: 2021
• Outros Autores: Costa,Dayane B., Plewka,Jacqueline, Santos,Maiara Aline, Turkiewicz,Maurício
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442021000100411
• topic: Pap smear; loss of follow-up; quality management

ABSTRACT Introduction: Cervical cancer is considered a public health problem, ranking fourth among the most common types of cancer worldwide. Objective: The present study aimed to gather information on the follow-up, and to verify adherence to the management recommended by the Brazilian Ministry of Health (MH) of women with cervical cytopathological results of atypical squamous cells of undetermined significance (ASC-US) and atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H), as well as to evaluate the quality of cytopathology tests of the laboratory that provides services to the Brazilian Unified Health System (SUS). Methods: Cervical cytopathology results of squamous atypia were researched between the years 2016 and 2017 in standardized requirements from the MH. The performance of the laboratory that carried out the cytopathology tests were analyzed using indexes recommended in the Internal Quality Monitoring (IQM) of the MH [Quality Management Manual (QMM)]. Results: 42,478 cytopathology tests were evaluated, 893 of these presented ASC-US results, and 199 ASC-H results. In women with ASC-US results, 73.2% repeated the cytopathology test, of which 18.7% remained the altered result, and 81.3% were negative for malignancy. Following the recommendation of the MH, 81.9% of women repeated the test outside the recommended period. In women with ASC-H, 51.8% underwent histopathological examination as recommended by the MH, of which 73.8% were altered. Conclusion: According to the MH Guidelines, most (81.9%) women with ASC-US repeated the cytopathology test